Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A.

Trial Profile

Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 May 2015

At a glance

  • Drugs GSK 1437173A (Primary) ; AS01B; AS01E
  • Indications Herpes zoster; Varicella zoster virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 10 Dec 2010 Planned end date changed from 1 Jun 2010 to 1 May 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top